Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

C. Mircea S. Tesileanu(Erasmus MC Cancer Institute), Martin J. van den Bent(Erasmus MC Cancer Institute), Warren Mason(Princess Margaret Cancer Centre), Anna K. Nowak(The University of Western Australia), Catherine McBain(Unknown), Kin Jip Cheung(Ineos (Belgium)), Matthew Griffin(Nottingham University Hospitals NHS Trust), Michael Weller(University Hospital of Zurich), Sanjeev Gill(The Alfred Hospital), Pim J. French(Erasmus MC Cancer Institute), Walter Taal(Heidelberg University), Iris de Heer(Erasmus MC Cancer Institute), Jean‐François Baurain(Cliniques Universitaires Saint-Luc), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Pieter Wesseling(Radboud University Nijmegen), Andreas von Deimling(German Cancer Research Center), Sara Erridge(The University of Texas MD Anderson Cancer Center), Kenneth Aldape(National Institutes of Health), Rutger W. W. Brouwer(Erasmus MC), Helen Wheeler(The University of Sydney), Marc Sanson(Centre National de la Recherche Scientifique), Johan M. Kros(Erasmus MC), Olivier Chinot(Aix-Marseille Université), Leland Rogers(NRG Oncology), Brigitta G. Baumert(Kantonsspital Graubünden), Wolfgang Wick(German Cancer Research Center), Youri Hoogstrate(Erasmus MC), Wilfred F. J. van IJcken(Erasmus MC), Myra E. van Linde(Amsterdam Neuroscience), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Roberta Rudà, Vassilis Golfinopoulos(Champalimaud Foundation), Michael A. Vogelbaum(Moffitt Cancer Center), Robert B. Jenkins(Mayo Clinic), Hendrikus J. Dubbink(Erasmus MC), Peggy N. Atmodimedjo(Erasmus MC Cancer Institute), Paul M. Clément(Universitair Ziekenhuis Leuven)
Clinical Cancer Research
March 11, 2022
Cited by 74


Related Papers